NephroGenex

About:

NephroGenex is a drug-development company focusing on kidney disease and progression of diabetic kidney disease.

Top Investors: Care Capital, BioStratum, Vanderbilt University Office of Investments, East West Bank

Description:

NephroGenex is a drug-development company focusing on kidney disease. The Company is developing Pyridorinâ„¢ (pyridoxamine dihydrochloride) as a treatment to slow the progression of diabetic kidney disease.

Total Funding Amount:

$21.8M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Princeton, New Jersey, United States

Founded Date:

2004-01-01

Founders:

Wesley Fox

Number of Employees:

11-50

Last Funding Date:

2015-11-13

IPO Status:

Delisted

Industries: